Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Amortization of Deferred Charges (2016 - 2025)

Ptc Therapeutics has reported Amortization of Deferred Charges over the past 13 years, most recently at $313000.0 for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $313000.0 for Q4 2025, up 1.95% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 1.75% YoY), and the annual figure for FY2025 was $1.2 million, up 1.75%.
  • Amortization of Deferred Charges for Q4 2025 was $313000.0 at Ptc Therapeutics, up from $306000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for PTCT hit a ceiling of $585000.0 in Q4 2022 and a floor of $182000.0 in Q3 2021.
  • Median Amortization of Deferred Charges over the past 5 years was $299500.0 (2023), compared with a mean of $336500.0.
  • Peak annual rise in Amortization of Deferred Charges hit 125.0% in 2021, while the deepest fall reached 92.04% in 2021.
  • Ptc Therapeutics' Amortization of Deferred Charges stood at $471000.0 in 2021, then increased by 24.2% to $585000.0 in 2022, then plummeted by 48.89% to $299000.0 in 2023, then rose by 2.68% to $307000.0 in 2024, then grew by 1.95% to $313000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were $313000.0 (Q4 2025), $306000.0 (Q3 2025), and $301000.0 (Q2 2025) per Business Quant data.